Nucala
GSK’s Nucala meets Phase 3 goal in reducing hypereosinophilic syndrome flare-ups
November 13, 2019Research and Development GSK, Nucala, pharma
GlaxoSmithKline has unveiled new Phase 3 data for its IL-5 inhibitor Nucala (mepolizumab), revealing that the therapy met its primary …
European approval for two new delivery formulations of GSK’s Nucala in severe eosinophilic asthma
August 2, 2019Medical Communications, Sales and Marketing Europe, GSK, Nucala, asthma, pharma
Following closely on the heels of the news that its deal to merge Pfizer’s consumer health business with its own, …
GSK’s Nucala data insufficient for US COPD approval
September 10, 2018Sales and Marketing COPD, FDA, GSK, Nucala, US, pharma
GlaxoSmithKline has suffered a regulatory blow in the label expansion of its interleukin-5 (IL5) inhibitor Nucala (mepolizumab), with the FDA …
AZ’s hopes for Fasenra in COPD suffer terminal blow
May 30, 2018Research and Development AstraZeneca, Fasenra, GSK, Nucala, biotech, drugs, pharma, pharmaceutical
It looked unlikely that Fasenra would achieve success in the chronic obstructive pulmonary disease (COPD) area, after it suffered in …
AZ’s Fasenra stumbles in P3 for COPD
May 11, 2018Medical Communications, Research and Development AstraZeneca, Fasenra, GSK, Nucala, biotech, drugs, pharma, pharmaceutical
AstraZeneca’s Fasenra arrived later on the scene than GSK rival med, Nucala, and so it needed to quickly rack up …
NICE recommends GSK’s “first-in-class” asthma drug
November 30, 2016Sales and Marketing GSK, NICE, Nucala, asthma
NICE has announced its recommendation of GSK’s “first-in-class” biologic Nucala (mepolizumab) as an extra option for the treatment of adults …
GSK’s Nucala gets regulatory approval in Japan to treat bronchial asthma
March 29, 2016Manufacturing and Production, Research and Development GlaxoSmithKline, Japan, Nucala, US FDA, bronchial asthma
GlaxoSmithKline (LSE: GSK) on Tuesday said the Japanese regulators have approved its drug to treat bronchial asthma. The Japanese Ministry …
GSK says long-term study for Nucala backs safety profile
March 8, 2016Manufacturing and Production, Research and Development GSK, GlaxoSmithKline, Nucala, asthma
UK pharma major GlaxoSmithKline (LSE: GSK) said its asthma drug, Nucala (mepolizumab) showed a similar safety profile in a long-term …
Researchers question price of GSK’s Nucala
December 23, 2015Research and Development GSK, HEOR, ICER, Nucala, asthma, cost-effective, health economics, health economics outcomes research
GSK is charging up to four times more for its recently approved asthma drug Nucala than is justified by cost-effectiveness …
GSK gets European approval for asthma treatment Nucala
December 3, 2015Research and Development GSK, Nucala, asthma
GlaxoSmithKline has received marketing authorisation from the European Commission for Nucala as an add-on treatment for severe refractory eosinophilic asthma …
GSK asthma drug Nucala gets FDA approval
November 6, 2015GSK, Nucala, asthma, eosinophils, mepolizumab
GlaxoSmithKline has received approval from the FDA for Nucala as an add-on maintenance treatment of patients with severe asthma aged …
Latest content
